How Genetically Engineered Mouse Tumor Models Provide Insights into Human Cancers

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2011 Jan 26

PMID 21263096

Citations 58

Authors

Katerina Politi

William Pao

Affiliations

Soon will be listed here.

Abstract

Genetically engineered mouse models (GEMMs) of human cancer were first created nearly 30 years ago. These early transgenic models demonstrated that mouse cells could be transformed in vivo by expression of an oncogene. A new field emerged, dedicated to generating and using mouse models of human cancer to address a wide variety of questions in cancer biology. The aim of this review is to highlight the contributions of mouse models to the diagnosis and treatment of human cancers. Because of the breadth of the topic, we have selected representative examples of how GEMMs are clinically relevant rather than provided an exhaustive list of experiments. Today, as detailed here, sophisticated mouse models are being created to study many aspects of cancer biology, including but not limited to mechanisms of sensitivity and resistance to drug treatment, oncogene cooperation, early detection, and metastasis. Alternatives to GEMMs, such as chemically induced or spontaneous tumor models, are not discussed in this review.

Citing Articles

Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability.

Kaifi J, Joshi K, Suvilesh K, Natesh N, Manjunath Y, Coberly J Res Sq. 2025; .

PMID: 39975891 PMC: 11838710. DOI: 10.21203/rs.3.rs-5054204/v1.

Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability.

Joshi K, Suvilesh K, Natesh N, Manjunath Y, Coberly J, Schlink S bioRxiv. 2024; .

PMID: 39569144 PMC: 11577786. DOI: 10.1101/2024.11.04.621940.

Canine on the Couch: The New Canary in the Coal Mine for Environmental Health Research.

Wise C, Breen M, Stapleton H Environ Health (Wash). 2024; 2(8):517-529.

PMID: 39170948 PMC: 11334179. DOI: 10.1021/envhealth.4c00029.

Application status and future prospects of the PDX model in lung cancer.

Liu W, Cui Y, Zheng X, Yu K, Sun G Front Oncol. 2023; 13:1098581.

PMID: 37035154 PMC: 10080030. DOI: 10.3389/fonc.2023.1098581.

Novel Mouse Models for Cancer Immunology.

Connolly K, Fitzgerald B, Damo M, Joshi N Annu Rev Cancer Biol. 2023; 6(1):269-291.

PMID: 36875867 PMC: 9979244. DOI: 10.1146/annurev-cancerbio-070620-105523.

References

Meylan E, Dooley A, Feldser D, Shen L, Turk E, OuYang C . Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009; 462(7269):104-7. PMC: 2780341. DOI: 10.1038/nature08462. View

Orsulic S . An RCAS-TVA-based approach to designer mouse models. Mamm Genome. 2002; 13(10):543-7. DOI: 10.1007/s00335-002-4003-4. View

Zhou Y, Rideout 3rd W, Zi T, Bressel A, Reddypalli S, Rancourt R . Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol. 2009; 28(1):71-8. DOI: 10.1038/nbt.1595. View

DuPage M, Dooley A, Jacks T . Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009; 4(7):1064-72. PMC: 2757265. DOI: 10.1038/nprot.2009.95. View

Pleasance E, Stephens P, OMeara S, McBride D, Meynert A, Jones D . A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2009; 463(7278):184-90. PMC: 2880489. DOI: 10.1038/nature08629. View

Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A . Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A. 2009; 106(7):2359-64. PMC: 2650161. DOI: 10.1073/pnas.0810221106. View

Jackson E, Olive K, Tuveson D, Bronson R, Crowley D, Brown M . The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005; 65(22):10280-8. DOI: 10.1158/0008-5472.CAN-05-2193. View

Lauchle J, Kim D, Le D, Akagi K, Crone M, Krisman K . Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009; 461(7262):411-4. PMC: 4119783. DOI: 10.1038/nature08279. View

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

10.

Hung K, Faca V, Song K, Sarracino D, Richard L, Krastins B . Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila). 2009; 2(3):224-33. PMC: 2874864. DOI: 10.1158/1940-6207.CAPR-08-0153. View

11.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

12.

Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D . Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010; 70(23):9827-36. PMC: 3043107. DOI: 10.1158/0008-5472.CAN-10-1671. View

13.

Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View

14.

Gandhi L, McNamara K, Li D, Borgman C, McDermott U, Brandstetter K . Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila). 2009; 2(4):330-7. PMC: 2696128. DOI: 10.1158/1940-6207.CAPR-08-0213. View

15.

Azam M, Latek R, Daley G . Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003; 112(6):831-43. DOI: 10.1016/s0092-8674(03)00190-9. View

16.

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View

17.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

18.

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346(9):645-52. DOI: 10.1056/NEJMoa011573. View

19.

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

20.

Harvey M, McArthur M, Montgomery Jr C, Butel J, Bradley A, Donehower L . Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993; 5(3):225-9. DOI: 10.1038/ng1193-225. View